Global Antibiotic Resistance Market
Antimicrobial substances used to treat bacterial infection which known as antibiotics. Also, they are used to heal a number of medical conditions such as sinus, stroke, ear infections, pneumonia, urinary tract infection, skin infections, and other diseases. Antibiotic resistance occurs naturally as well as misuse of antibiotics in humans would raise the growth of antibiotic resistance.
Market Drivers
The increase in burden of antibiotic-resistant infections and emergence of multi-drug resistant pathogens has been contributing the global antibiotic resistance market growth over the forecast period. Majority of pharmaceutical companies including Novartis, Johnson & Johnson, GlaxoSmithKline, and Sanofi find the lucrative enough due to relatively slower growth in revenues for marketed drugs & lower return on investments. For Example, Novartis had canceled all plans to continue with research and development for its antibacterial drugs. Also, there are various biotech companies such as Achaogen, Melinta Therapeutics, and Nabriva Therapeutics which have undertaken the challenge of developing therapies for antibiotic resistance.
The increase in incidence of chronic & infectious disease is anticipated to propel the growth of global antibiotic resistance market. For example, approximately 17 million people were affected by contagious across the globe. Furthermore, the increase in clinical developments of antibiotic resistance is expected to boost the target market growth over the forecast period. For Example, In June 2019, around 42 new antibiotic resistance with the potential to treat bacterial infections are in clinical development.
Market Restraints
Limited number of manufacturers in the field of antibiotic resistance as well as lack of investment from major market players is expected to hamper the global antibiotic resistance market growth during this forecast period.
Market Segmentation
The Global Antibiotic Resistance Market is segmented into Disease such as Complicated Urinary Tract Infection (cUTI), Complicated Intra-Abdominal Infections (cIAI), Blood Stream Infections (BSI), Clostridium difficile infections (CDI), Acute Bacterial Skin and Skin Structure Infections (ABSSSI),Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP), and Community Acquired Bacterial Pneumonia (CABP), by Pathogen such as Acinetobacter baumannii (Carbapenem-Resistant and ESBL-producing), Pseudomonas aeruginosa (Carbapenem-Resistant),Staphylococcus Aureus (Methicillin-Resistant), E. coli/K. pneumonia (Carbapenem-Resistant),Streptococcus pneumoniae (Penicillin-Non-Susceptible),Clostridium difficile (Cephalosporin-Resistant, Tetracycline-Resistant), Enterococcus faecium (Vancomycin-Resistant), and Haemophilus Influenzae (Ampicillin-Resistant). Further, market is segmented into drug class such as Oxazolidinones, Lipoglycopeptides, Tetracyclines, Cephalosporins, Combination therapies, and Others.
Also, the Global Antibiotic Resistance Market is segmented into five regions such as North America, Latin America, Europe, Asia Pacific, and Middle East & Africa.
Regional Analysis
The Asia Pacific is projected to dominate the antibiotic resistance market in terms of revenue, on account of nations including China, and India where an elevated incidence of bacterial infections is reported. Also, the increase in awareness of individuals about antibiotic resistance in this region, North America & Europe is also contributing the global antibiotic resistance market growth in terms of revenue, due to availability of better medical equipment is propelling the development of antibiotic resistance market in this region.
Market Key Players
Various key players are listed in this report such as Achaogen, Inc, PARATEK therapeutics, MELINTA THERAPEUTICS, INC, Basilea Pharmaceutica Ltd., Theravance Biopharma, Entasis Therapeutics, Allecra Therapeutics, Procarta Biosystems, NEMESIS BIOSCIENCE LTD, Nabriva Therapeutics plc, etc.
Market Taxonomy
By Disease
By Pathogen
By Drug Class
By Region
Key Questions Addressed by the Report
Global Antibiotic Resistance Market TOC
1 Introduction
1.1 Objective of the Study
1.2 Market definition
1.3 Market Scope
2 Research Methodology
2.1 Data Mining
2.2 Validation
2.3 Primary Interviews
2.4 List of Data Sources
3 Executive Summary
4 Global Antibiotic Resistance Market Outlook
4.1 Overview
4.2 Market Dynamics
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis
5 Global Antibiotic Resistance Market, By Disease
5.1 Y-o-Y Growth Comparison, By Disease
5.2 Global Antibiotic Resistance Market Share Analysis, By Disease
5.3 Global Antibiotic Resistance Market Size and Forecast, By Disease
5.3.1 Complicated Urinary Tract Infection (cUTI)
5.3.2. Complicated Intra-Abdominal Infections (cIAI)
5.3.3. Blood Stream Infections (BSI)
5.3.4. Clostridium difficile infections (CDI)
5.3.5. Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
5.3.6. Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
5.3.7. Community Acquired Bacterial Pneumonia (CABP)
6 Global Antibiotic Resistance Market, By Pathogen
6.1 Y-o-Y Growth Comparison, By Pathogen
6.2 Global Antibiotic Resistance Market Share Analysis, By Pathogen
6.3 Global Antibiotic Resistance Market Size and Forecast, By Pathogen
6.3.1 Acinetobacter baumannii (Carbapenem-Resistant and ESBL-producing)
6.3.2. Pseudomonas aeruginosa (Carbapenem-Resistant)
6.3.3. Staphylococcus Aureus (Methicillin-Resistant)
6.3.4. E. coli/K. pneumoniae (Carbapenem-Resistant)
6.3.5. Streptococcus pneumoniae (Penicillin-Non-Susceptible)
6.3.6. Clostridium difficile (Cephalosporin-Resistant, Tetracycline-Resistant)
6.3.7. Enterococcus faecium (Vancomycin-Resistant)
6.3.8. Haemophilus Influenzae (Ampicillin-Resistant)
7 Global Antibiotic Resistance Market, By Drug Class
7.1 Y-o-Y Growth Comparison, By Drug Class
7.2 Global Antibiotic Resistance Market Share Analysis, By Drug Class
7.3 Global Antibiotic Resistance Market Size and Forecast, By Drug Class
7.3. 1 Oxazolidinones
7.3.2. Lipoglycopeptides
7.3.3. Tetracyclines
7.3.4. Cephalosporins
7.3.5. Combination therapies
7.3.6. Others
8Global Antibiotic Resistance Market, By Region
8.1 Global Antibiotic Resistance Market Share Analysis, By Region
8.2 Global Antibiotic Resistance Market Share Analysis, By Region
8.3 Global Antibiotic Resistance Market Size and Forecast, By Region
9 North America Antibiotic Resistance Market Analysis and Forecast (2020-2030)
9.1 Introduction
9.2 North America Antibiotic Resistance Market Share Analysis, By Disease
9.3 North America Antibiotic Resistance Market Size and Forecast, By Pathogen
9.4 North America Antibiotic Resistance Market Size and Forecast, By Drug Class
9.5 North America Antibiotic Resistance Market Size and Forecast, By Country
9.5.1 U.S.
9.5.2 Canada
9.5.3 Mexico
10EuropeAntibiotic Resistance Market Analysis and Forecast (2020-2030)
10.1 Introduction
10.2 Europe Antibiotic Resistance Market Share Analysis, By Disease
10.3 Europe Antibiotic Resistance Market Size and Forecast, By Pathogen
10.4 Europe Antibiotic Resistance Market Size and Forecast, By Drug Class
10.5 Europe Antibiotic Resistance Market Size and Forecast, By Country
10.5.1 Germany
10.5.2 France
10.5.3 UK
10.54. Rest of Europe
11Asia Pacific Antibiotic Resistance Market Analysis and Forecast (2020-2030)
11.1 Introduction
11.2 Asia Pacific Antibiotic Resistance Market Share Analysis, By Disease
11.3 Asia Pacific Antibiotic Resistance Market Size and Forecast, By Pathogen
11.4 Asia Pacific Antibiotic Resistance Market Size and Forecast, By Drug Class
11.5 Asia Pacific Antibiotic Resistance Market Size and Forecast, By Country
11.5.1 China
11.5.2 Japan
11.5.3 India
11.5.4. Rest of Asia Pacific
12Latin America Antibiotic Resistance Market Analysis and Forecast (2020-2030)
12.1 Introduction
12.2 Latin America Antibiotic Resistance Market Share Analysis, By Disease
12.3 Latin America Antibiotic Resistance Market Size and Forecast, By Pathogen
12.4 Latin America Antibiotic Resistance Market Size and Forecast, By Drug Class
12.5 Latin America Antibiotic Resistance Market Size and Forecast, Country
13Middle East Antibiotic Resistance Market Analysis and Forecast (2020-2030)
13.1 Introduction
13.2 Middle East Antibiotic Resistance Market Share Analysis, By Disease
13.3 Middle East Antibiotic Resistance Market Size and Forecast, By Pathogen
13.4 Middle East Antibiotic Resistance Market Size and Forecast, By Drug Class
13.5 Middle East Antibiotic Resistance Market Size and Forecast, By Country
14Competitive Analysis
14.1 Competition Dashboard
14.2 Market share Analysis of Top Vendors
14.3 Key Development Strategies
15Company Profiles
15.1 Achaogen, Inc
15.1.1 Overview
15.1.2 Offerings
15.1.3 Key Financials
15.1.4 Business Segment & Geographic Overview
15.1.5 Key Market Developments
15.1.6 Key Strategies
15.2. PARATEK therapeutics
15.2.1 Overview
15.2.2 Offerings
15.2.3 Key Financials
15.2.4 Business Segment & Geographic Overview
15.2.5 Key Market Developments
15.2.6 Key Strategies
15.3. MELINTA THERAPEUTICS, INC
15.3.1 Overview
15.3.2 Offerings
15.3.3 Key Financials
15.3.4 Business Segment & Geographic Overview
15.3.5 Key Market Developments
15.3.6 Key Strategies
15.4 Basilea Pharmaceutica Ltd
15.4.1 Overview
15.4.2 Offerings
15.4.3 Key Financials
15.4.4 Business Segment & Geographic Overview
15.4.5 Key Market Developments
15.4.6 Key Strategies
15.5 Theravance Biopharma
15.5.1 Overview
15.5.2 Offerings
15.5.3 Key Financials
15.5.4 Business Segment & Geographic Overview
15.5.5 Key Market Developments
15.5.6 Key Strategies
15.6 Entasis Therapeutics
15.6.1 Overview
15.6.2 Offerings
15.6.3 Key Financials
15.6.4 Business Segment & Geographic Overview
15.6.5 Key Market Developments
15.6.6 Key Strategies
15.7 Allecra Therapeutics
15.7.1 Overview
15.7.2 Offerings
15.7.3 Key Financials
15.7.4 Business Segment & Geographic Overview
15.7.5 Key Market Developments
15.7.6 Key Strategies
15.8 Procarta Biosystems
15.8.1 Overview
15.8.2 Offerings
15.8.3 Key Financials
15.8.4 Business Segment & Geographic Overview
15.8.5 Key Market Developments
15.8.6 Key Strategies
15.9 NEMESIS BIOSCIENCE LTD
15.9.1 Overview
15.9.2 Offerings
15.9.3 Key Financials
15.9.4 Business Segment & Geographic Overview
15.9.5 Key Market Developments
15.9.6 Key Strategies
15.10 Nabriva Therapeutics plc
15.10.1 Overview
15.10.2 Offerings
15.10.3 Key Financials
15.10.4 Business Segment & Geographic Overview
15.10.5 Key Market Developments
15.10.6 Key Strategies
